Ratings Dr. Martens plc

Equities

DOCS

GB00BL6NGV24

Market Closed - London S.E. 16:35:03 24/05/2024 BST 5-day change 1st Jan Change
86.15 GBX +0.88% Intraday chart for Dr. Martens plc +1.35% -2.77%

Summary

  • On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses

  • As estimated by analysts, this group is among those businesses with the lowest growth prospects.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Footwear

1st Jan change Capi. Investor Rating ESG Refinitiv
-2.77% 1.06B
C+
+54.53% 26.51B
B+
+29.43% 10.98B
C+
+9.54% 10.42B
C
+59.43% 9.04B
B-
-1.27% 9.04B -
-5.52% 7.76B
A-
+19.90% 3.39B
A-
+75.00% 3.12B
B-
-8.96% 2.46B
C
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. DOCS Stock
  4. Ratings Dr. Martens plc